greeksoup/ stock research
Stock research / United States / ISRG · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq

Intuitive Surgical Inc. (ISRG)

Intuitive Surgical makes robotic-assisted systems for minimally invasive care, along with the instruments and accessories they consume, customer learning and support services, and a digital portfolio connecting them. It was founded over 30 years ago. The company had approximately 17,021 full-time employees at the end of 2025, about 7,625 of them in manufacturing operations. Domestic revenue was 68 percent of total revenue in 2025, against 67 percent in 2024 and 66 percent in 2023, with markets outside the United States making up the rest.

Intuitive Surgical Inc.

Intuitive Surgical makes robotic-assisted systems for minimally invasive care, along with the instruments and accessories they consume, customer learning and support services, and a digital portfolio connecting them. It was founded over 30 years ago. The company had approximately 17,021 full-time employees at the end of 2025, about 7,625 of them in manufacturing operations. Domestic revenue was 68 percent of total revenue in 2025, against 67 percent in 2024 and 66 percent in 2023, with markets outside the United States making up the rest.

Da Vinci

The first da Vinci surgical system launched in 1999 and the FDA cleared it for general laparoscopic surgery in 2000; clearances have since widened across general surgery, urologic, gynecologic, cardiothoracic and head and neck specialties. Several generations are in use at once: the fifth-generation da Vinci 5, the fourth-generation X, Xi and SP, and the third-generation Si. Da Vinci 5 builds on the Xi design and adds force feedback, letting surgeons sense and measure the force exerted on tissue, and carries an operating room informatics platform. Its installed base was 1,231 systems at the end of 2025, after FDA clearance in March 2024 and a phased rollout outside the United States. The da Vinci SP, aimed at narrow workspaces, had an installed base of 377 systems and is in an early, measured rollout.

Ion

The Ion endoluminal system, cleared by the FDA in 2019, is a flexible catheter-based robotic platform whose first cleared indication is minimally invasive biopsies in the lung. It extends the company beyond surgery into diagnostic endoluminal procedures. The catheter is ultra-thin and articulates 180 degrees in all directions, with real-time shape-sensing technology for navigating all segments of the lung. The filing's argument for it is that suspicious lung lesions are often small and hard to reach, and Ion lets physicians take tissue from deep in the peripheral lung, which may allow earlier diagnosis.

Instruments and accessories

Stapling, energy and core instrumentation are made for the da Vinci systems. The technology turns the surgeon's hand movements outside the body into micro-movements inside it, with motion scaling translating a three-millimetre hand movement into a one-millimetre instrument movement, and the tremor in a surgeon's hands filtered out. Most instruments carry wristed joints and tips customised for particular procedures, including forceps, scissors, electrocautery tools and scalpels, and can be swapped during a single operation. Most are sterilisable at the hospital and reusable, others supplied sterile.

Digital solutions

The digital products draw on data from the network of connected surgical systems, which also lets the company monitor product performance and push software updates. Intuitive 3D Models is an augmented reality imaging service for kidney, prostate, lung and rectal procedures: CT and MR scans go through segmentation algorithms, technicians revise and radiologists review, and the output is a 3D segmented model of the organ showing blood vessels and tumour shape and size. It is used for pre-operative planning, for showing surgeons where critical anatomy sits as they work, and as a teaching tool, and it has recently launched.

The procedure mix

The da Vinci business splits into cancer procedures and procedures for benign conditions. Cancer and other highly complex procedures tend to be reimbursed at higher rates, so hospitals are more sensitive to the cost of treating less complex benign conditions. The product line is positioned along that spectrum: da Vinci 5 and Xi with advanced instruments, including the energy and stapler products and Integrated Table Motion, target the complex end, while X is aimed at price-sensitive customers and SP reaches narrow workspaces. United States procedures grew approximately 15 percent in 2025, matching 2024, led by general surgery and gynecologic surgery, and procedures outside the United States grew approximately 23 percent, also matching 2024.

How it sells

Direct sales organisations cover the United States, most of Europe, China through majority-owned joint ventures with Fosun Pharma, Japan, South Korea, India, Taiwan and Canada. Distributors are used alongside the direct force for some government customers in the United States and in China and Japan, and on their own across the remaining markets. The direct organisation splits in two: a capital sales team selling the systems and a clinical sales team supporting them in use at hospital accounts, which include individual hospitals and facilities within integrated delivery networks. The first system sale into an account is a major capital equipment purchase with a lengthy sales cycle, affected by macroeconomic conditions, capital spending priorities and budgeting cycles. The clinical team works on site, helping identify interested surgeons and sustain a hospital's robotic programme.

From Intuitive Surgical's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in Intuitive Surgical became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 21 October 2026
Revenue
$3.0 billion
+21.7% on the year · +5.4% on the quarter
Q4 FY2024Q3 FY2026
Net income
$523 million
-25.8% on the year · -36.1% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$1.49
-23.6% on the year · -34.9% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 3 February 2026
Revenue
$10.1 billion
+20.5% on the year
FY2018FY2025
Net income
$2.9 billion
+23.0% on the year
FY2018FY2025
Diluted EPS
$7.87
+22.6% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsIntuitive Surgical (ISRG) reported revenue of $10.1 billion for fiscal 2025, the year ended 31 December 2025, up 20.5% on the year before. Net income was $2.9 billion and diluted earnings per share $7.87. Revenue was $8.4 billion in fiscal 2024, $7.1 billion in fiscal 2023, $6.2 billion in fiscal 2022 and $5.7 billion in fiscal 2021. Net income in the same years was $2.3 billion, $1.8 billion, $1.3 billion and $1.7 billion. Over the twelve months to 30 September 2026, Intuitive Surgical reported revenue of $11.6 billion and net income of $3.0 billion. Revenue grew 18.2% a year, compounded, over the five years to fiscal 2025. Intuitive Surgical had 347 million shares outstanding at the latest filed count. At 30 September 2026 it carried $0 million of debt and $3.0 billion of cash. At the close of 6 November 2026 the market cap of Intuitive Surgical was $156.9 billion, 54.7 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROE18.5%
ROCE20.5%
Operating margin28.4%
Net margin25.5%
FCF margin31.1%
Interest covern/a
Debt to equity0.00x
Cash conversion1.38x
Share count, last 12 months-2.3%
Sales CAGR, 3 years17.4%
Profit CAGR, 3 years29.3%
EPS, TTM$8.27

At the close of 6 November 2026

Price$452.76
Market cap$156.9 billion
Stock P/E54.8x
Price to book9.8x
EV / EBITDAn/a
Dividend yieldn/a
Market cap / sales13.6x
52-week high$592.85
52-week low$332.02
Price, 1 year-17.3%
Price CAGR, 3 years17.6%
Price CAGR, 5 years4.4%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Intuitive Surgical Inc.'s balance sheet shows no borrowings, so debt here is nil; lease liabilities are a separate line. Nothing here is a valuation or a view.
ISRGgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021Q1 FY2022 †Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue1,5511,4881,5221,5571,6551,6961,7561,7441,9281,8912,0102,0382,4142,2532,4402,5052,8662,7712,8923,049
Cost of revenue490478499505544583584576651645637664771796822843962940932964
Gross profit1,0611,0101,0231,0521,1111,1131,1721,1671,2771,2451,3731,3741,6421,4581,6181,6621,9041,8301,9602,084
Gross margin68%68%67%68%67%66%67%67%66%66%68%67%68%65%66%66%66%66%68%68%
R&D183210207217244245244249260284280286295316313329353362371408
SG&A427391418436494480464452567492525511613563561573687613618633
Operating income450408398399372388463466450469567577735578743760864855972593
Operating margin29%27%26%26%23%23%26%27%23%25%28%28%30%26%30%30%30%31%34%19%
Pre-tax income4544024074033954224995225165386546718106688328559569401,055668
Tax rate16%8%23%19%15%14%15%20%-18%-2%19%15%15%-5%20%17%16%12%22%22%
Net income381366308324325355421416606545527565686698658704795822818523
Net margin25%25%20%21%20%21%24%24%31%29%26%28%28%31%27%28%28%30%28%17%
Diluted EPS$1.03$1.00$0.85$0.90$0.91$1.00$1.18$1.16$1.69$1.51$1.46$1.56$1.88$1.92$1.81$1.95$2.21$2.28$2.29$1.49
Operating cash flow5682234473834383716665482282656207068235827158418929121,0611,224
Capital expenditure15193.6130169138194178256436242309248312117155105162103113113
Free cash flow417129316214300177487292-20723.53114595114655607367308099481,111
Buybacks0.01065001,0001,0013500.00.066.30.00.00.00.00.01811,9132011,1233202,976
Dividends paidn/an/an/an/an/an/an/a0.0n/an/an/a0.0n/an/an/a0.0n/an/an/an/a
Shares outstanding358m359m357m353m350m350m351m352m352m355m355m356m357m358m358m355m355m354m354m347m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2007FY2008 †FY2009 †FY2010 †FY2011FY2012 †FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue6018751,0521,4131,7572,1792,2652,1322,3842,7063,1383,7244,4784,3585,7106,2227,1248,35210,06511,578
Cost of revenue1872543013834846086717188068149351,1201,3681,4971,7522,0262,3952,7183,4223,798
Gross profit4146217511,0301,2741,5701,5941,4141,5781,8902,2022,6043,1102,8613,9584,1964,7305,6346,6427,780
Gross margin69.0%71.0%71.4%72.9%72.5%72.1%70.4%66.3%66.2%69.8%70.2%69.9%69.4%65.6%69.3%67.4%66.4%67.5%66.0%67.2%
Research and development48.979.495.11161401701681781972403294185575956718799991,1451,3121,494
Selling, general and administrative1592312793594395225746916407048119871,1781,2161,4661,7401,9642,1402,3852,552
Operating income2073113775556958788525457409501,0631,1991,3741,0501,8211,5771,7672,3492,9463,284
Operating margin34.4%35.5%35.9%39.3%39.5%40.3%37.6%25.6%31.0%35.1%33.9%32.2%30.7%24.1%31.9%25.3%24.8%28.1%29.3%28.4%
Pre-tax income2373353965727108948715497589851,1051,2801,5021,2071,8901,6071,9592,6743,3113,619
Income tax92.7131164190215237200130170247434154120140162262142336435646
Effective tax rate39.1%39.0%41.3%33.3%30.2%26.5%23.0%23.7%22.4%25.1%39.3%12.1%8.0%11.6%8.6%16.3%7.2%12.6%13.1%17.8%
Net income1452042333824956576714195897386711,1281,3791,0611,7051,3221,7982,3232,8562,957
Net margin24.1%23.4%22.1%27.0%28.2%30.1%29.6%19.6%24.7%27.3%21.4%30.3%30.8%24.3%29.9%21.3%25.2%27.8%28.4%25.5%
Diluted EPS$0.41$0.57$0.66$1.05$1.37$1.78$1.86$1.23$1.73$2.09$1.92$3.16$3.85$2.94$4.66$3.65$5.03$6.42$7.87$8.27
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by product or service FY2016 to FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
Instruments and accessories1,3961,6371,9622,4082,4563,1003,5184,2775,0796,01959.8%
Systems8009281,1271,3461,1791,6931,6801,6801,9662,47424.6%
Service5115736357247249161,0241,1681,3071,57215.6%
Instruments and accessoriesSystemsService
3.1FY20174.5FY20195.7FY20217.1FY202310.1FY2025

$ billion; hover a block for its figure and share

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

Cash flow

FY2007FY2008 †FY2009 †FY2010 †FY2011FY2012 †FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow2062783925466788148806658061,0871,1441,1701,5981,4852,0891,4911,8142,4153,0304,090
Capital expenditure24.010653.496.082.911410510681.053.91911874263423405321,0641,111540492
Free cash flow1821723394505957007755607251,0339539821,1731,1431,7509587501,3042,4913,598
Free cash flow margin30.2%19.7%32.2%31.8%33.8%32.1%34.2%26.2%30.4%38.2%30.4%26.4%26.2%26.2%30.6%15.4%10.5%15.6%24.7%31.1%
Cash from investing-236-305-300-494-479-846259-154-850-1,279379-1,050-1,154-941-2,4621,371-360-3,273666747
Cash from financing11998.0-66.27.7-12.4119-911-692159514-1,913126-168-85.743.0-2,572-288151-2,364-4,673
Depreciation and amortisation13.025.134.640.446.557.867.374.485.588.995.0120200270307354402456613n/a
Share-based compensation36.376.697.0118136153169169168178209261336395449513593677788835
Buybacks0.00.01501993322381,1091,00018442.52,2740.02701340.02,6074160.02,2954,620
Diluted shares, weighted351m359m353m363m362m370m361m339m341m354m349m356m358m361m366m362m357m362m363m352m
Shares outstanding at period endn/a353m346m350m354m362m344m329m337m116m337m344m348m353m358m350m352m357m355m347m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2007FY2008 †FY2009 †FY2010 †FY2011FY2012 †FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equity8891,2671,5372,0372,6463,5803,5013,3794,3205,7784,7796,6798,2649,73211,90111,04213,30816,43417,82415,986
Non-controlling interestn/an/an/an/an/an/an/an/an/a0.01.68.720.927.650.470.789.795.9118132
Debtn/an/an/a0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/an/an/an/a68.758.066.669.664.5112132n/a
Other liabilitiesn/a2082723534184794495805887099961,1591,3801,3521,5371,7921,9802,1012,3853,231
Total liabilities and equityn/a1,4751,8102,3903,0634,0593,9503,9594,9076,4875,7777,8479,73311,16913,55512,97415,44218,74320,45919,349
Owned
Fixed assetsn/a1171261601972423103874324586138121,2731,5771,8762,3743,5384,6475,3425,676
Goodwilln/a111111117117138137198201201201241307337344348349348370558
Intangible assetsn/a56.256.266.171.083.664.374.149.731.526.066.711277.470.549.839.123.017.1197
Investmentsn/a7079511,3291,7062,3671,9721,8972,6333,8013,1983,9764,6785,2467,3295,1604,5936,8055,6663,822
Trading assetsn/an/a62.2n/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a
Cash and equivalents1231952212804665547826007151,0376488581,1681,6231,2911,5812,7502,0273,3682,978
Receivablesn/a1702052472983703013153944305086826456467839421,1301,2251,5271,721
Inventoryn/a63.557.686.81121221801821681822414095966025878931,2211,4871,8402,128
Other assetsn/a55.219.810596.21832043063143463418029551,0611,2751,6251,8222,1812,3282,268
Total assetsn/a1,4751,8102,3903,0634,0593,9503,9594,9076,4875,7777,8479,73311,16913,55512,97415,44218,74320,45919,349
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded15.5%18.2%17.4%20.5%
Profit growth, compounded17.1%21.9%29.3%7.7%
Return on equity, average14.1%14.0%14.6%16.0%
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was Intuitive Surgical's revenue in fiscal 2025?

Intuitive Surgical (ISRG) reported revenue of $10.1 billion for fiscal 2025, the year ended 31 December 2025, up 20.5% on the year before.

How much did Intuitive Surgical earn in fiscal 2025?

Net income was $2.9 billion for fiscal 2025, and diluted earnings per share $7.87.

What is Intuitive Surgical's P/E ratio?

At the close of 6 November 2026, Intuitive Surgical traded at 54.7 times its earnings over the twelve months to 30 September 2026.

What is Intuitive Surgical's market cap?

The market cap of Intuitive Surgical was $156.9 billion at the close of 6 November 2026.

How much debt does Intuitive Surgical have?

At 30 September 2026 Intuitive Surgical carried $0 million of debt and $3.0 billion of cash.

Peers: Medical Equipment

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
All 110 in Medical Equipment
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Intuitive Surgical Inc. ISRG$156.9 billion54.7518.5%28.4%20.5%0.00n/a
Medtronic plc MDT$130.3 billion25.0710.4%18.1%9.8%0.562.8%
Stryker Corp. SYK$124.0 billion34.7015.4%20.7%7.9%0.641.1%
3M Co. MMM$95.7 billion27.6185.7%18.8%1.7%3.631.7%
Boston Scientific Corp. BSX$62.0 billion18.1113.7%18.7%8.9%0.47n/a
Edwards Lifesciences Corp. EW$58.8 billion57.679.4%21.6%13.4%0.06n/a
Becton Dickinson & Co. BDX$57.7 billion63.803.9%9.6%-2.6%0.692.0%
Medline Inc. MDLN$52.2 billion57.614.9%5.7%n/a1.07n/a
GE HealthCare Technologies Inc. GEHC$37.2 billion17.3818.5%13.3%6.9%0.860.2%
Resmed Inc. RMD$33.1 billion21.4226.8%33.0%9.0%0.071.0%
Dexcom Inc. DXCM$29.6 billion31.1439.1%24.0%13.0%0.49n/a
Koninklijke Philips N.V. PHG *$29.2 billion29.228.2%8.0%-1.0%0.741.3%
West Pharmaceutical Services Inc. WST$27.9 billion44.8721.5%23.0%12.6%0.070.2%
Steris plc STE$24.5 billion29.9311.4%19.0%8.1%0.261.0%
Zimmer Biomet Holdings, Inc. ZBH$20.0 billion26.736.0%13.6%7.0%0.590.9%
Solventum Corp. SOLV$15.4 billion101.513.2%5.6%-2.8%1.05n/a
Smith & Nephew plc SNN *$13.7 billion21.7611.8%12.9%6.1%0.592.4%
Baxter International Inc. BAX$13.3 billionn/a-11.1%-1.9%5.3%1.322.0%
Glaukos Corp. GKOS$13.3 billionn/a-23.7%-25.5%46.9%0.00n/a
Penumbra Inc. PEN$12.6 billion80.459.9%12.1%17.0%0.00n/a
Cooper Companies, Inc. COO$11.9 billion21.296.8%12.8%4.7%0.31n/a
Align Technology Inc. ALGN$11.7 billion24.1711.4%14.9%4.4%0.00n/a
Insulet Corp. PODD$10.2 billion23.8727.2%18.4%26.5%0.61n/a
Globus Medical Inc. GMED$9.5 billion17.4511.6%21.6%13.4%0.00n/a
Bausch & Lomb Corp. BLCO$7.1 billionn/a-1.7%7.1%8.9%0.79n/a
MSA Safety Inc. MSA$6.6 billion21.8621.1%20.2%8.1%0.781.3%
Teleflex Inc. TFX$6.0 billion18.338.7%9.4%20.9%0.460.9%
Haemonetics Corp. HAE$5.5 billion53.8311.6%12.8%4.1%1.26n/a
Merit Medical Systems Inc. MMSI$5.2 billion32.809.2%13.5%9.1%0.42n/a
LivaNova plc LIVN$5.0 billion30.0114.3%10.7%11.7%0.22n/a
MiniMed Group, Inc. MMED$4.7 billionn/an/an/an/a0.00n/a
Heartflow, Inc. HTFL$4.5 billionn/a-42.3%-37.8%n/a0.00n/a
Integer Holdings Corp. ITGR$4.3 billion42.486.0%8.2%-0.3%0.71n/a
ICU Medical Inc. ICUI$4.3 billion71.992.8%5.1%-5.9%0.53n/a
Envista Holdings Corp. NVST$4.0 billion6.5120.5%25.4%9.8%0.46n/a
Pulse Biosciences, Inc. PLSE$3.9 billionn/a-45.6%-5,821.1%1,637.2%0.00n/a
Warby Parker Inc. WRBY$3.2 billion424.581.9%0.2%9.9%0.00n/a
TransMedics Group, Inc. TMDX$3.1 billion23.8926.2%11.9%28.5%0.930.0%
iRhythm Holdings, Inc. IRTC$3.0 billionn/a-21.8%-5.7%21.6%3.68n/a
Axogen, Inc. AXGN$3.0 billionn/a-6.4%-5.2%24.3%0.00n/a
AtriCure, Inc. ATRC$3.0 billion195.032.8%2.9%13.8%0.11n/a
UFP Technologies Inc. UFPT$2.3 billion30.9015.8%15.5%8.6%0.20n/a
Establishment Labs Holdings Inc. ESTA$2.0 billionn/a-246.6%-6.6%38.3%17.17n/a
Dentsply Sirona Inc. XRAY$1.9 billionn/a-8.9%-1.5%-1.4%1.626.8%
Lemaitre Vascular Inc. LMAT$1.9 billion29.4214.7%27.7%11.8%0.391.2%
Inspire Medical Systems, Inc. INSP$1.8 billion18.5712.2%1.8%-0.2%0.00n/a
Kestra Medical Technologies, Ltd. KMTS$1.7 billionn/a-67.4%-134.5%60.7%0.33n/a
Butterfly Network, Inc. BFLY$1.7 billionn/a-29.1%-46.9%39.3%0.000.0%
Enovis Corp. ENOV$1.6 billionn/a-35.3%-20.6%3.3%0.84n/a
NovoCure Ltd. NVCR$1.6 billionn/a-34.7%-17.2%12.9%0.56n/a
Conmed Corp. CNMD$1.5 billion21.306.9%9.9%1.6%0.771.2%
National Vision Holdings, Inc. EYE$1.4 billion29.335.6%4.1%7.8%0.26n/a
Cadre Holdings, Inc. CDRE$1.4 billion34.4211.2%10.7%18.3%1.011.2%
Staar Surgical Co. STAA$1.3 billion1,815,851,369,755,783,936.000.1%0.2%42.4%0.00n/a
Procept BioRobotics Corp. PRCT$1.2 billionn/a-34.9%-33.6%17.5%0.16n/a
Tandem Diabetes Care Inc. TNDM$1.2 billionn/a-36.4%-2.4%6.8%4.47n/a
Alphatec Holdings, Inc. ATEC$1.2 billionn/an/a-3.6%15.3%n/an/a
Iradimed Corp. IRMD$1.1 billion46.1422.5%32.3%11.0%0.000.9%
Si-Bone, Inc. SIBN$1.1 billionn/a-7.4%-7.6%14.0%0.190.0%
Integra LifeSciences Holdings Corp. IART$1.0 billion78.971.2%4.4%0.8%1.71n/a
Ceribell, Inc. CBLL$1.0 billionn/a-62.9%-69.8%31.3%0.17n/a
Artivion, Inc. AORT$986 millionn/a-3.9%2.3%14.0%0.81n/a
Bioventus Inc. BVS$893 million13.2523.8%9.7%3.9%0.96n/a
Beta Bionics, Inc. BBNX$855 millionn/a-20.7%-72.7%43.7%0.00n/a
Orthopediatrics Corp. KIDS$828 millionn/a-10.0%-9.4%16.1%0.31n/a
Tactile Systems Technology Inc. TCMD$585 million25.2610.5%9.4%14.4%0.00n/a
Sight Sciences, Inc. SGHT$558 millionn/a-57.8%-29.5%16.2%0.83n/a
Anteris Technologies Global Corp. AVR$553 millionn/a-41.2%-4,738.4%-9.6%0.00n/a
Delcath Systems, Inc. DCTH$517 million1,494.000.4%-1.9%35.8%0.00n/a
Avita Medical, Inc. RCEL$513 millionn/an/a-33.9%17.0%n/an/a
Angiodynamics Inc. ANGO$497 millionn/a-20.1%-11.2%8.2%0.00n/a
Mimedx Group, Inc. MDXG$482 millionn/a-9.1%-8.3%-22.8%0.00n/a
SS Innovations International, Inc. SSII$430 millionn/a-23.3%-15.8%89.7%0.00n/a
NeuroPace Inc. NPCE$428 millionn/a-160.9%-15.3%11.6%4.970.0%
Shoulder Innovations, Inc. SI$426 millionn/a-28.2%-54.4%n/a0.13n/a
Cerus Corp. CERS$407 millionn/a-9.7%-1.0%n/a0.84n/a
Carlsmed, Inc. CARL$395 millionn/a-43.1%-61.1%n/a0.18n/a
Mobia Medical, Inc. MOBI$372 millionn/an/an/an/a0.05n/a
Embecta Corp. EMBC$350 million4.18n/a21.9%-7.6%n/a7.4%
Orchestra BioMed Holdings, Inc. OBIO$341 millionn/a-305.5%-181.4%986.1%1.80n/a
Orthofix Medical Inc. OFIX$320 millionn/a-14.4%-4.7%3.0%0.52n/a
CapsoVision, Inc. CV$316 millionn/a-226.6%-217.1%n/a0.00n/a
Cytosorbents Corp. CTSO$308 millionn/an/a-34.7%3.1%n/an/a
Sanara MedTech Inc. SMTI$291 millionn/a-403.0%n/a12.9%5.85n/a
ClearPoint Neuro, Inc. CLPT$276 millionn/a-132.5%-70.6%32.5%1.86n/a
InfuSystem Holdings, Inc. INFU$272 million33.3414.4%9.3%2.5%0.35n/a
Treace Medical Concepts, Inc. TMCI$265 millionn/a-90.5%-24.4%-7.1%0.91n/a
Profound Medical Corp. PROF$264 millionn/a-76.4%-145.1%65.3%0.11n/a
Orasure Technologies Inc. OSUR$238 millionn/a-15.5%-48.1%-18.9%0.00n/a
Utah Medical Products Inc. UTMD$231 million22.138.6%28.4%-7.0%0.00n/a
Electromed, Inc. ELMD$226 million20.5820.9%18.8%15.3%0.00n/a
PRO DEX Inc. PDEX$202 million17.3524.4%16.8%13.3%0.33n/a
TriSalus Life Sciences, Inc. TLSI$200 millionn/a-430.7%-67.7%25.2%5.05n/a
Anika Therapeutics, Inc. ANIK$195 millionn/a-1.3%-2.1%9.4%0.00n/a
RxSight, Inc. RXST$190 millionn/a-20.9%-50.4%-14.3%0.00n/a
Inogen Inc. INGN$161 millionn/a-14.1%-8.7%3.2%0.00n/a
Edap TMS SA FOCL$158 millionn/a-104.3%-35.4%n/a0.99n/a
Koru Medical Systems, Inc. KRMD$143 millionn/a-10.1%-3.7%22.4%0.00n/a
Apyx Medical Corp. APYX$124 millionn/a-87.6%-5.5%24.4%3.89n/a
Pulmonx Corp. LUNG$112 millionn/a-124.4%-44.4%-3.2%1.11n/a
Stereotaxis, Inc. STXS$111 millionn/a-182.3%-75.7%-5.5%0.00n/a
SkinHealth Systems Inc. SKIN$102 millionn/a-32.8%2.4%-4.4%4.36n/a
Lakeland Industries Inc. LAKE$88 millionn/a-21.4%-4.1%-0.4%0.23n/a
Outset Medical, Inc. OM$79 millionn/a-85.4%-51.2%1.6%1.18n/a
Neuraxis, Inc. NRXS$77 millionn/a-114.0%-144.5%65.2%0.01n/a
Lucid Diagnostics Inc. LUCD$76 millionn/a-478.3%-930.8%24.9%2.15n/a
Lensar, Inc. LNSR$66 millionn/a232.8%-13.5%3.3%0.25n/a
NutriBand Inc. NTRB$66 millionn/a-130.7%-435.6%-37.3%0.00n/a
RenovoRx, Inc. RNXT$55 millionn/a-140.2%-489.0%n/a0.00n/a
PAVmed Inc. PAVM$10 millionn/a-34.5%-23,841.1%-89.0%0.43n/a
14 companies share its SEC industry code (Orthopedic, Prosthetic & Surgical Appliances & Supplies); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on ISRG

Dividendsno dividend in its filings for fiscal 2007 onward
Filings20 in twelve months: 11 current reports (8-K), about 5 results of operations; 4 officer or director change; 2 regulation FD disclosure; 1 charter or bylaw amendment, or fiscal year change; 1 shareholder vote
Planned insider sales44 Form 144 notices in twelve months, $102.1 million; latest 4 November 2026
Options tapeput/call 0.82 by open interest at the 6 November 2026 close; the straddle prices a 4.1% move to 13 November 2026
13F holders2,269 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading83 sales and 0 purchases on Form 4 in twelve months
Congress0 House trades disclosed in six months
Short interest7.3 million shares short, 4.05 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 5 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 202621 October 2026EDGAR
10-Q30 June 202621 July 2026EDGAR
10-Q31 March 202622 April 2026EDGAR
10-K31 December 20253 February 2026EDGAR
10-Q30 September 202522 October 2025EDGAR
10-Q30 June 202523 July 2025EDGAR
10-Q31 March 202523 April 2025EDGAR
10-K31 December 202431 January 2025EDGAR
10-Q30 September 202418 October 2024EDGAR
10-Q30 June 202419 July 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.